당뇨병성 신경병증 환자에서 hsCRP와 비복신경전도검사의 관계
Relationship between Serum hsCRP Level and Sural Nerve Conduction Study in Diabetic Neuropathy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: High sensitivity C-reactive protein (hsCRP) has been known to correlate well with diabetes mellitus type 2. In this study, we assessed the correlation between the hsCRP and the diabetic polyneuropathy which is one form of the microangiopathic complication of diabetes mellitus using the amplitude of the sural nerve action potential. Methods: Serum hsCRP levels were checked within one week from the electrodiagnostic study for the diabetic polyneuropathy and we reviewed the patients who were diagnosed as having a diabetic polyneuropathy after the electrodiagnostic study. Finally, Thirty-Six patients were analyzed for the correlation identification between the serum hsCRP level and the amplitude of sural nerve conduction study. Results: The characteristics of the patients were amplitude of sural nerve of 7.4±4.0 ㎶ and mean serum hsCRP level of 0.44±0.67 mg/L. With bivariate correlation analysis, there were no linear correlation between the serum hsCRP level and the amplitude of sural nerve (p=0.797). Conclusion: hsCRP as a novel marker of microangiopathy did not show the significant correlation with amplitude of the sural nerve action potential in this study. Although microangiopathy is one of the pathophysiology of the diabetic polyneuropathy, the serum hsCRP level has doubtful meaning in diagnosis or assessment of the diabetic polyneuropathy yet.
Abstract
Objectives: High sensitivity C-reactive protein (hsCRP) has been known to correlate well with diabetes mellitus type 2. In this study, we assessed the correlation between the hsCRP and the diabetic polyneuropathy which is one form of the microangiopathic complication of diabetes mellitus using the amplitude of the sural nerve action potential. Methods: Serum hsCRP levels were checked within one week from the electrodiagnostic study for the diabetic polyneuropathy and we reviewed the patients who were diagnosed as having a diabetic polyneuropathy after the electrodiagnostic study. Finally, Thirty-Six patients were analyzed for the correlation identification between the serum hsCRP level and the amplitude of sural nerve conduction study. Results: The characteristics of the patients were amplitude of sural nerve of 7.4±4.0 ㎶ and mean serum hsCRP level of 0.44±0.67 mg/L. With bivariate correlation analysis, there were no linear correlation between the serum hsCRP level and the amplitude of sural nerve (p=0.797). Conclusion: hsCRP as a novel marker of microangiopathy did not show the significant correlation with amplitude of the sural nerve action potential in this study. Although microangiopathy is one of the pathophysiology of the diabetic polyneuropathy, the serum hsCRP level has doubtful meaning in diagnosis or assessment of the diabetic polyneuropathy yet.
참고문헌 (19)
- Festa A, "Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study", Diabetes, 51, pp.1131~1137 (2002)
- Pradhan AD, "C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus", JAMA, 286, pp.327~334 (2001)
- Jager A, "Von Wilebrand factor, C-reactive protein, and 5-year mortality in diabetic and non-diabetic subjects: the Hoorn Study", Arterioscler Thromb Vasc Biol, 19, pp.3071~3078 (1999)
- de Ferranti SD, "C-reactive protein: a nontraditional serum marker of cardiovascular risk", Cardiovasc Pathol, 16, pp.14~21 (2007)
- Amato AA, "Acquired neuropathies. in: Electrodiagnostic medicine, 2nd ed", pp.979~983 (2002), Hanley & Belfus
- Jialal I, "Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker", Am J Clin Pathol, 116, pp.S108~S115 (2001)
- Bassuk SS, "High-sensitivity C-reactive protein: clinical importance", Curr Probl Cardiol, 29, pp.439~493 (2004)
- 박주현, "당뇨병성 신경병증 환자에서 족부맥박 검사에 따른 전기진단학적 비교", Annals of Rehabilitation Medicine, 28(4), pp.539~544 (2003), 대한재활의학회
- "The Diabetes Control and Complication Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy", Ann Intern Med, 122, pp.561~568 (1995)
- Dinarello CA, "Interleukin-1 and the pathogenesis of the acute-phase response", N Engl J Med, 311, pp.1413~1418 (1984)
- Abdellaoui A, "C-reactive protein (CRP) as a marker in peripheral vascular disease", Eur J Vasc Endovasc Surg, 34, pp.18~22 (2007)
- Pearson TA, "Centers for Disease Control and Prevention; American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association", Circulation, 28, pp.499~511 (2003)
- Lin Y, "Hyperglycemia-induced production of acute phase reactants in adipose tissue", J Biol Chem, pp.42077~42083 (2001)
- Han TS, "Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study", Diabetes Care, 25, pp.2016~2021 (2002)
- Kang ES, "Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes", Diabetes Res Clin Pract, 69, pp.151~159 (2005)
- Claus D, "Assessment of diabetic neuropathy: definition of norm and discrimination of abnormal nerve function", Muscle Nerve, 16, pp.757~768 (1993)
- Malik RA, "Endoneurial localisation of microvascular damage in human diabetic neuropathy", Diabetologia, 36, pp.454~459 (1993)
- Zochodne DW, "Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms", Muscle Nerve, 36, pp.144~166 (2007)
- Theriault M, "Local human sural nerve blood flow in diabetic and other polyneuropathies", Brain, 120, pp.1131~1138 (1997)